Growth Metrics

KalVista Pharmaceuticals (KALV) Asset Utilization Ratio (2015 - 2025)

KalVista Pharmaceuticals recorded quarterly Asset Utilization Ratio of 0.31 in Q3 2025, up 412.41% quarter-over-quarter from 0.06 in Q2 2025, and up 619.87% year-over-year from 0.04 in Q3 2024.

KalVista Pharmaceuticals' Asset Utilization Ratio history runs 8 years deep, the most recent figure standing at 0.31 for Q3 2025.

  • In Q3 2025, Asset Utilization Ratio rose 619.87% year-over-year to 0.31; the TTM figure through Jul 2025 stood at 0.31 (up 619.87% YoY), while the FY2025 annual figure was 0.05, down 81.06% from the prior year.
  • Asset Utilization Ratio came in at 0.31 for Q3 2025 at KalVista Pharmaceuticals, up from 0.06 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.31 in Q3 2025 to a low of 0.04 in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.60
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.47
7 Evaxion A 62.56 Bn 62.54 Bn - 0.29
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.37
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.85
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn 0.31

Historic Data

Download Data 🔒
DateValue
Jul 31, 2025 0.31
Apr 30, 2025 0.06
Jul 31, 2024 0.04
Apr 30, 2020 0.13
Jan 31, 2020 0.11
Oct 31, 2019 0.12
Jul 31, 2019 0.13
Apr 30, 2019 0.13
Jan 31, 2019 0.14
Oct 31, 2018 0.17
Jul 31, 2018 0.20
Apr 30, 2018 0.13
Jan 31, 2018 0.07
Oct 31, 2017 0.05
Jul 31, 2017 0.02
Apr 30, 2017 0.04
Mar 31, 2016 0.00
Dec 31, 2015 0.00
Sep 30, 2015 0.00
Jun 30, 2015 0.00
Mar 31, 2015 0.00